

# GLOBAL LIFE SCIENCES FUND


## Sector experts seeking growth through innovation in healthcare

A powerful combination of factors are driving long-term sustainable growth in the healthcare sector: innovation, aging populations and rising living standards that lead to higher healthcare spending globally. By understanding the science and business of healthcare, the fund invests in companies addressing unmet medical needs or making the healthcare system more efficient.

### 1. Opportunities for innovation

Accelerating innovation is addressing unmet medical needs. The 261 drugs approved between 2019-2023 represent a 116% increase compared to the 5-year period from 2004-2008<sup>1</sup>.


Number of Drugs Receiving FDA Approval<sup>1</sup>



### 2. Balanced approach

The portfolio is diversified across geographies, market capitalisations and the primary sub-sectors of healthcare. This helps us to broadly capture opportunities in the sector.


Portfolio Composition<sup>2</sup>



### 3. Defensive characteristics

The sector provides potential diversification. It has typically held up better in down markets.


Performance and Downside Capture<sup>3</sup>



### 4. Attractive valuation potential

Healthcare traded at a premium to the equity market more than half of the time over the past 29 years. Biotech, where a vast majority of the innovation is occurring, is trading at a discount to the broader equity markets which is unusual.<sup>4</sup>

Historical Healthcare Valuations (1 year forward P/E)<sup>4</sup>  
(31/12/94 – 31/12/23)



# Global Life Sciences Fund (as of 31 December 2023)

## Why Janus Henderson?


- ▶ **Experienced and specialised investment team** with over a century of combined experience investing in the complex and dynamic healthcare sector
- ▶ **Importance of active management** – Our team focuses on the clinical, commercial and construction risks to identify companies poised to succeed. The disparity between winners and losers provides a great opportunity to outperform
- ▶ Investment team managing US\$10.7bn in asset under management<sup>5</sup>

## Why the Fund?


- ▶ **Healthcare expertise:** Our team is highly specialised and differentiated in terms of interests and therefore coverage: biochemical sciences, immunology, medical materials, medical technology and biological chemistry are areas of deep knowledge
- ▶ **Differentiated fundamental research:** By understanding both the science and business of companies, we seek to uncover the compelling opportunities across the life sciences spectrum and around the world
- ▶ **Integrated risk management process:** Security-level “Value at Risk” framework focuses on risk management by limiting the position size of any one holding based on the assessment of downside risk

## Portfolio allocation<sup>7</sup>

### Country Breakdown (%)



### Industry Breakdown (%)



## Fund performance<sup>6</sup>

Annualised Performance (%)	1M	YTD	1Y	5Y	Since Launch
A2 USD	7.42	5.44	5.44	10.62	7.06
A2 USD (with sales charge) <sup>^</sup>	2.05	0.17	0.17	9.49	6.83
Benchmark	4.42	3.76	3.76	10.47	7.55
A2 SGD	6.02	3.88	3.88	-	7.94
A2 SGD (with sales charge) <sup>^</sup>	0.72	-1.31	-1.31	-	6.80
Benchmark	3.21	2.04	2.04	-	8.84
A2 HSGD	7.15	3.79	3.79	-	7.61
A2 HSGD (with sales charge) <sup>^</sup>	1.80	-1.40	-1.40	-	6.47
Benchmark	3.21	2.04	2.04	-	8.84

<sup>^</sup>Performance with sales charge assume 5.00% initial sales charge/front-end load (FEL) applied. **Past performance is no guarantee of future results.**

## Fund facts

Fund manager	Andy Acker, CFA	
Launch date	31 March 2000 (A2 USD) 11 March 2019 (A2 SGD, A2 HSGD)	
Benchmark	MSCI World Healthcare Index	
Base currency	USD	
ISIN	IE00BFTCPJ56 IE00BJT1NW94 IE0009355771 IE00BJJMRZ35 IE0002141913 IE00B2B36J28	(A2 SGD) (A2 HSGD) (A2 USD) (I2 HSGD) (I2 USD) (I1 USD)
Fund size <sup>7</sup>	USD 3.70bn	
Morningstar rating <sup>8</sup>	★★★★	
Initial charge	Up to 5%	
Management fee	1.5% pa	

FOR MORE INFORMATION, PLEASE VISIT [JANUSHENDERSON.COM](http://JANUSHENDERSON.COM)

**Janus Henderson**  
INVESTORS

Unless otherwise indicated, the source for all data is Janus Henderson Investors, as at 31 December 2023. Source: 1. FDA, as at 31 December 2023. 2. Janus Henderson Investors, as at 31 December 2023. 3. Janus Henderson Investors, FactSet, as at 31 December 2022. Chart reflects market declines of 15% or greater in the MSCI World Index<sup>SM</sup> since 2000. 4. Bloomberg, as at 31 December 2023. Healthcare: S&P 500<sup>®</sup> Health Care Index; Equity market: S&P 500<sup>®</sup> Index; Biotech: S&P 500<sup>®</sup> Biotechnology Industry GICS Level 3 Index. 5. Janus Henderson Investors, as at 30 September 2023. 6. Morningstar, as at 31 December 2023. Performance is net of fees, with gross income reinvested. Performance figures of less than 1 year are not annualized. Benchmark: MSCI World Healthcare Index. Peers: Morningstar Category - Sector Equity Healthcare. Fund inception date: 31 March 2000. 7. Janus Henderson Investors, as at 31 December 2023. 8. Morningstar, Sector Equity Healthcare, Class A2 USD, as of 31 December 2023. **Past performance is no guarantee of future results.**

The views presented are as of the date published. They are for information purposes only and should not be used or construed as investment, legal or tax advice, or as an offer to sell, a solicitation of an offer to buy, or a recommendation to buy, sell or hold any security, investment strategy or market sector. Nothing in this material shall be deemed to be a direct or indirect provision of investment management services specific to any client requirement. Opinions and examples are meant as an illustration of broader themes, are not an indication of trading intent, are subject to change and may not reflect the views of others in the organization. It is not intended to indicate or imply that any illustration/example mentioned is now or was ever held in any portfolio. No forecasts can be guaranteed and there is no guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its use. Janus Henderson is the source of data unless otherwise indicated, and has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance is no guarantee of future results. Investing involves risk, including the possible loss of principal and fluctuation of value.** Not all products or services are available in all jurisdictions. This material or information contained in it may be restricted by law, and may not be reproduced or referred to without express written permission or used in any jurisdiction or circumstance in which its use would be unlawful. Janus Henderson is not responsible for any unlawful distribution of this material to any third parties, in whole or in part. The contents have not been approved or endorsed by any regulatory agency. Issued in **Singapore** by Janus Henderson Investors (Singapore) Limited (Co. registration no. 199700782N) licensed and regulated by the Monetary Authority of Singapore. This advertisement has not been reviewed by the Monetary Authority of Singapore. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. The value of an investment and the income from it can fall as well as rise and investors may not get back the amount originally invested. There is no assurance stated objective(s) will be met. There is no assurance that the investment process discussed includes an effort to monitor and manage risk which should not be confused with and does not imply low risk or the ability to control certain risk factors. Various account minimums or other eligibility qualifications apply depending on the investment strategy, vehicle of investor jurisdiction. Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. The Singapore Representative of the Janus Henderson Capital Funds plc is Janus Henderson Investors (Singapore) Limited and is distributed by authorised distributors. The Prospectus and Product Highlights Sheet of the Fund is available and may be obtained from the Singapore Representative's office and the authorised distributors' offices. Investors should read the prospectus and Product Highlights Sheet before deciding whether to invest in the units of the Fund. Portfolio characteristics are for illustration and subject to change. CFA<sup>®</sup> and Chartered Financial Analyst<sup>®</sup> are trademarks owned by CFA Institute. © 2023 Morningstar. All rights reserved. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc. SG5774 200-99-119005 12-23